Home > Insider Trading > Filing (0000950170-24-069553)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1812364	Relay Therapeutics Inc.	RLAY	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1959229	Peter Rahmer	C/O Relay Therapeutics, Inc. 399 Binney Street, 2Nd Floor Cambridge MA 02139	See Remarks	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2024-06-03	19,864	$6.47	493,470	No	4	S	Direct
Common Stock	Disposition	2024-06-04	40,595	$6.64	452,875	No	4	S	Direct
Common Stock	Disposition	2024-06-05	20,450	$7.06	432,425	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 80,909 shares of restricted stock units ("RSUs") on May 31, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.
Includes 384,434 shares underlying RSUs.
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 22, 2024.
This transaction was executed in multiple trades at prices ranging from $6.56 to $6.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
This transaction was executed in multiple trades at prices ranging from $6.97 to $7.18. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.